The United Kingdom finally cast off from the European Union on Friday for an uncertain future, with Brexiteers claiming victory and popping champagne corks for an "independence day" they said marked a new era for the country.
from Reuters: World News https://ift.tt/2tgjcSM
Singing patriotic songs and waving Union Jacks, thousands of Britons flocked to a muddy patch of grass outside parliament on a damp Friday night to toast their moment of history: Britain's departure from the European Union.
from Reuters: World News https://ift.tt/31isNVY
On the last train to Europe before Britain left the EU on Friday evening, passengers leaving London expressed sorrow, optimism and anger, reflecting the emotions of a nation conflicted ahead its great leap into the unknown.
from Reuters: World News https://ift.tt/2S8yTE8
Nicaragua's best known former political prisoner, Amaya Coppens, is calling for international organizations to investigate alleged abuses by the government of President Daniel Ortega.
from Reuters: World News https://ift.tt/36O3cVI
President Donald Trump on Friday relaxed Obama-era restrictions on the U.S. military's use of anti-personnel land mines, arguing that the previous policy could put American troops at a "severe disadvantage."
from Reuters: World News https://ift.tt/2Oh3gqN
China's Hubei province, the epicentre of a coronavirus epidemic, reported 45 new deaths from the outbreak on Friday, bringing the total to 249, the local health commission said on Saturday.
from Reuters: World News https://ift.tt/37Lfgs9
Reuters) - The Trump administration, while insisting the risk to Americans from coronavirus is low, nevertheless declared a public health emergency on Friday and announced the extraordinary step of barring entry to the United States of foreign nationals who have traveled to China.
from Reuters: World News https://ift.tt/37NPKT8
The United Kingdom finally cast off from the European Union on Friday for an uncertain Brexit future, turning its back on post-World War Two attempts to unite the once warring nations of Europe into a global power.
from Reuters: World News https://ift.tt/3b0qTNU
Airlines are suspending flights to China in the wake of the new coronavirus outbreak, which as of Friday had killed more than 200 people and infected nearly 10,000 people.
from Reuters: World News https://ift.tt/2RP9f8B
Some companies have warned that a coronavirus outbreak in China that has killed more than 200 people and infected thousands could disrupt supply chains or hurt bottom lines as factories and shops shut and airlines suspend flights.
from Reuters: World News https://ift.tt/2uNurTb
U.S. President Donald Trump will issue an expanded version of his travel ban on Friday that targets prospective immigrants from Nigeria and five other countries, U.S. officials said, a move that could affect thousands of people and reignite debate over whether the policy is discriminatory.
from Reuters: World News https://ift.tt/2GEnIh8
(Bloomberg) -- U.S. health regulators approved the first drug for children and teenagers with peanut allergies, marking a potential paradigm shift in treatment.The drug, which will be sold under the brand name Palforzia, will be marketed by Aimmune Therapeutics Inc.. The therapy involves ingesting small doses of peanut protein, gradually increased over time to help desensitize patients to higher levels. The medicine is similar to oral therapies offered by some allergists; however, it is the first to be cleared by the U.S. Food and Drug Administration.Shares of Aimmune jumped 22% in extended trading Friday to $37.90 a share. The stock had gained 32% over the past 12 months.The drug will be “a game changer for both food allergy doctors and patients,” according to Christina Ciaccio, an associate professor of pediatrics at the University of Chicago and an investigator for Palforzia in U.S. studies. “To date, we have not been able to do anything but tell patients to carefully monitor what they are eating and to always be prepared with an epinephrine autoinjector in case a reaction does occur.”The new drug is not a cure for patients and studies show it may not work for everyone that receives it. However, Aimunne says the benefits can be life-changing for parents and children who worry about the potentially fatal effects of accidental exposure.Palforzia is intended to appeal to patients and allergists who want regulated therapy that is trusted and has a consistent protocol, according to Chief Executive Officer Jayson Dallas. The approval is “a defining moment for the entire peanut allergy community” and can “help usher in a new era in the treatment of peanut allergy and, in the long term, for food allergy in general,” Dallas said in a message to Bloomberg News.The drug’s path to approval was rocky at times as a government shutdown to start 2019 meant the FDA didn’t begin reviewing Aimmune’s application as early as investors hoped. Shares have climbed since September when an advisory panel to the FDA voted in favor of the drug.“Peanut allergy impacts patients and their families on a daily basis and the threat of a severe reaction related to an accidental peanut exposure creates anxiety and interferes with their quality of life,” Dallas said.The company compares the dosing regimen to that of allergy shots; there are 12 visits during the first six months of increasing doses, followed by daily dosing at home. While the current label is for patients between four and 17 years old, the company is studying the medicine in toddlers between one and four years old.Analysts expect Palforzia to start slow with about $48 million in sales this year, rising to $1.2 billion in 2024, data compiled by Bloomberg show. The stock has high short interest, at about 30% of the available shares, according to financial analytics firm S3 Partners.Aimmune can “buck the trend” of the typical “short-the-launch” biotech thesis, Piper Jaffray analyst Christopher Raymond wrote in a note to clients in December.University of Chicago’s Ciaccio echoed that sentiment, saying she has already scheduled patients for treatment upon approval and even has a six month wait to set up a visit. While the drug will “not be a universal fit” for all patients, she looks forward to the day where there are multiple treatments to offer patients and decide which is the best fit.Of the roughly 3 million people in the U.S. with peanut allergies, Aimmune says about half of them would meet the target age group of four to 17. The Brisbane, California-based company sees a similar opportunity in Europe.Aimmune says it has identified about 1,300 allergists that they see as ready and willing adopters for the therapy when it becomes commercially available. Of that group, around 250 are already using do-it-yourself oral immunotherapy in their offices. Aimmune set the wholesale acquisition cost to $890 a month, regardless of the stage in patient dosing.Given elevated share prices and the fact that experienced allergists can treat patients using peanut flour at a much cheaper cost, there are some skeptics on Wall Street. Credit Suisse analyst Evan Seigerman sees upside for the stock as limited heading into what he called a “challenging commercial story.”Seigerman downgraded shares near the end of 2019, saying there could be “hiccups” in the timing of approval and launch given it is Aimmune’s first commercial drug.Aimmune’s approval paves the way for DBV Technologies SA and its experimental patch for peanut allergies. The FDA plans to make a decision on the Viaskin peanut patch by Aug. 5 after an advisory panel meeting.Brisbane, California-based Aimmune intends to use both digital and social media to help inform patients and families of the drug with hopes that they can consult with their allergist on potential treatment.(Adds acquisition cost in 14th paragraph.)\--With assistance from Jeremy R. Cooke.To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editor responsible for this story: Catherine Larkin at clarkin4@bloomberg.netFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
from Yahoo Finance https://ift.tt/38W3hIt
By ZOLAN KANNO-YOUNGS from NYT U.S. https://ift.tt/2Uc7EuO
As the cost of living continues to rise, more people are relocating for retirement to get more for their money. Live and Invest Overseas Co-Founder Lief Simon joins The Final Round to break down the best places in the world to retire.
from Yahoo Finance https://ift.tt/2Oh0Atf
The United Kingdom finally cast off from the European Union on Friday for an uncertain future, with Brexiteers claiming victory and popping champagne corks for an "independence day" they said marked a new era for the country.
from Reuters: Top News https://ift.tt/2RPf8CJ
